– USA, CA – Aether Biomachines, Inc, a leading enzyme engineering company building a future of abundance, today announced the appointment of Dr. Austin Che (Ph.D.) to its Board of Directors.
“Austin brings a skillset and perspective that will help us realize that vision. We are thrilled to have him join our Board of Directors and help us expand the Aether enzyme engineering platform to drive the next industrial revolution and help our society to thrive in a post-scarcity future,” said Pavle Jeremic, Founder and CEO of Aether Biomachines.
Austin Che joins Board of Directors with
- Shlomo Yanai, former CEO of Teva Pharmaceuticals,
- Stuart Peterson, Managing Partner of Founder of ARTIS Ventures,
- Vasudev Bailey, Senior Partner at ARTIS Ventures,
- Pavle Jeremic, Aether’s CEO and Founder.
About Austin Che
As co-founder of Ginkgo Bioworks, Austin Che brings over 10 years of experience in biotechnology, genetic engineering, and an executive track record of scaling one of the world’s most respected synthetic biology companies. Founded in 2008 by Che and his colleagues from Massachusetts Institute of Technology, Che played a critical role in developing Ginkgo’s platform to program cells as easily as computers across a wide variety of applications including food, agriculture, industrial chemicals, and pharmaceuticals. Che helped take Ginkgo Bioworks public in 2021 in a deal worth $15B and the company continues to produce custom organisms for a wide range of industries.
Austin Che holds a Ph.D. in Computer Science from the Massachusetts Institute of Technology, and a Bachelor of Science in Computer Science and Psychology from Stanford University.
“Aether’s integrated technologies for intelligently searching and engineering enzyme sequences has enormous potential,” said Austin Che. “I look forward to working with Aether’s talented leadership team to further develop these innovative approaches and push the boundaries of what is possible with enzyme engineering and biotechnology.”
About Aether Biomachines
Aether is a leading enzyme engineering company building a future of abundance for humankind in a post-scarcity future. The company is catalyzing the next industrial revolution by building the world’s highest throughput robotic laboratory, generating data on scales previously not possible to feed deep AI algorithms, and searching and mapping enzyme sequences to unlock and create new materials, therapeutics, and molecular products previously unimaginable.
With artificial intelligence at the core of its technology, Aether is building the world’s highest throughput robotic factory and proprietary processes and hardware to generate datasets of unprecedented size and complexity. The company’s multidimensional platform solves the “scalability” issues that currently bottleneck the industry and pushes the boundaries of what is possible with hardware, process, and algorithmic innovation. This holistic approach allows Aether to unlock novel chemistry that is impossible today and design new products and applications.
For more information: https://www.aetherbio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
